drugset / Trial / NCT07240987
Mesenchymal Stem Cells for Chronic Kidney Diseases
Phase 1/2
Not yet recruiting
32 enrolled
The First Affiliated Hospital of Air Force Medicial University
Non-randomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UMSCs | Cell therapy | 1e+06 cells/kg | Intravenous |